Capricor Therapeutics Inc (CAPR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Capricor Therapeutics Inc stock (CAPR) is currently trading at $28.87. Capricor Therapeutics Inc PS ratio (Price-to-Sales) is 124.43. Analyst consensus price target for CAPR is $53.90. WallStSmart rates CAPR as Sell.
- CAPR PE ratio analysis and historical PE chart
- CAPR PS ratio (Price-to-Sales) history and trend
- CAPR intrinsic value — DCF, Graham Number, EPV models
- CAPR stock price prediction 2025 2026 2027 2028 2029 2030
- CAPR fair value vs current price
- CAPR insider transactions and insider buying
- Is CAPR undervalued or overvalued?
- Capricor Therapeutics Inc financial analysis — revenue, earnings, cash flow
- CAPR Piotroski F-Score and Altman Z-Score
- CAPR analyst price target and Smart Rating
Capricor Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Capricor Therapeutics Inc (CAPR) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Capricor Therapeutics Inc (CAPR) Key Strengths (2)
Growing significantly faster than its price suggests
54.03% held by institutions, strong professional interest
Supporting Valuation Data
Capricor Therapeutics Inc (CAPR) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -7.90%, a shrinking business
Very expensive at 124.4x annual revenue
Very expensive at 5.5x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Capricor Therapeutics Inc (CAPR) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own.. Valuation metrics including PEG Ratio (0.38) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (124.43), Price/Book (5.46) suggest expensive pricing. Growth concerns include Revenue Growth at -7.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -46.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -46.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -7.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CAPR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CAPR's Price-to-Sales ratio of 124.43x trades at a deep discount to its historical average of 364.77x (51th percentile). The current valuation is 96% below its historical high of 2923.81x set in Apr 2008, and 11010% above its historical low of 1.12x in Dec 2012. Over the past 12 months, the PS ratio has expanded from ~28.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Capricor Therapeutics Inc (CAPR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Capricor Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 11M with 8% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 208% of revenue (23M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 8% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -2.0B, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Capricor Therapeutics Inc.
Bottom Line
Capricor Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Capricor Therapeutics Inc(CAPR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.